Paclitaxel-coated balloons using iopromide or urea matrices reduced neointimal area compared to uncoated controls (e.g., 2.0 vs 6.8 mm2 at 3 μg/mm2 dose) in a porcine coronary model.
Do paclitaxel-coated balloon catheters reduce neointimal proliferation in a porcine coronary overstretch model?
In a porcine model, paclitaxel-coated balloons effectively reduced neointimal proliferation at doses as low as 1 μg/mm2, with thrombotic events occurring only at intentionally excessive overlapping doses.
Absolute Event Rate: 2% vs 6.8%
OBJECTIVE: There is little published information regarding the efficacy of paclitaxel-coated balloon catheters except for the iopromide-containing formulation, and less is known about the kind of toxicity at overdose. The aim of our study was to assess 2 different paclitaxel matrix formulations on angioplasty balloon catheters in vitro, with respect to pharmacokinetics, and efficacy and tolerance to determine the minimum effective dose and local toxicity at extremely high dose which is only achieved in experimental studies. METHODS AND MATERIALS: Adherence of coatings was tested in vitro in dry state and during passage through hemostatic valves, guiding catheters, and blood. Drug release, transfer to the vessel wall during coronary angioplasty, inhibition of neointimal proliferation, and tolerance were investigated in swine. Efficacy and tolerance of balloons were examined for doses ranging from 1 to 9 μg/mm2 and 3 overlapping applications of balloons coated with 3 times the regular dose of 3 μg/mm2. Paclitaxel concentrations were determined by high performance liquid chromatography, efficacy and tolerance by vital signs, clinical observation, quantitative coronary angiography, and histomorphometry 4 weeks after implanting premounted bare stents in coronary arteries applying 1:1.2 overstretch. RESULTS: Under worst-case conditions, drug loss on the way through the guiding catheter and blood was in the range of 30%. After inflation of balloons coated with the clinically tested dose of 3 μg/mm2 in a coronary artery about 10% of drug remained on balloons, 20% to 30% was taken up into the vessel wall (∼200 μg). Neointimal area on cross sections was 6.8 ± 2.2 mm2 (uncoated control); 3.1 ± 1.1 mm2 (iopromide-matrix) and 3.0 ± 0.5 mm2 (urea-matrix) at 1 μg/mm2; 2.0 ± 0.4 mm2 versus 1.7 ± 1.1 mm2 at 3 μg/mm2 with no further decrease at higher doses. Thrombotic occlusions were observed in 3 of 15 vessel segments treated with overlapping inflations of 3 high-dose balloons but without any signs of aneurysms. CONCLUSION: In the animal model, 2 paclitaxel matrix formulations were similar in respect of uptake in the vessel wall, and effective already at a dose of 1 μg/mm2. Except thrombotic events for the intentionally excessive dose, paclitaxel-coated balloons were well tolerated in the animal model.
Kelsch et al. (Tue,) conducted a other in Coronary overstretch and stent implantation. Paclitaxel-coated balloon catheters (iopromide-matrix and urea-matrix) vs. Uncoated control was evaluated on Neointimal area on cross sections. Paclitaxel-coated balloons using iopromide or urea matrices reduced neointimal area compared to uncoated controls (e.g., 2.0 vs 6.8 mm2 at 3 μg/mm2 dose) in a porcine coronary model.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: